|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 239.30 EUR | -0.42% |
|
+2.22% | +0.29% |
| 05-12 | H Lundbeck raises 2026 forecasts on US demand, delayed generic competition | RE |
| 05-07 | UCB: New partnership with Cancer Research UK and Cancer Research Horizons | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 53.4B | |||||
| 72.53B | |||||
| 44.97B | |||||
| 34.1B | - | ||||
| 28.25B | |||||
| 19.85B | - |
- Stock Market
- Equities
- UCB Stock
- Charts UCB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition